Track ShockWave Medical, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

ShockWave Medical, Inc. SWAV · Stock Open ShockWave Medical, Inc. in new tab

334.75 USD
P/E
85.25
EPS
3.84
P/B
18.11
ROE
24.96
Beta
0.90
Target Price
316.14 USD
Loading chart...
Key Metrics
Earnings dateMay 6, 2024
P/E85.25
EPS3.84
Book Value18.08
Price to Book18.11
Debt/Equity115.24
% Insiders1.289%
Growth
Revenue Growth0.41%
Earnings Growth-0.69%
Estimates
Forward P/E52.97
Forward EPS6.18
Target Mean Price316.14

DCF valuation

Model fair value for ShockWave Medical, Inc. (SWAV)
Result
Sign in to run the valuation for SWAV.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 316.14 USD (low 210.00, high 368.00)
Low 210.00
Mean 316.14
High 368.00
Price 334.75
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

ShockWave Medical, Inc. Logo ShockWave Medical, Inc. Analysis (SWAV)

United States Health Care Official Website Stock

Is ShockWave Medical, Inc. a good investment? ShockWave Medical, Inc. (SWAV) is currently trading at 334.75 USD. Market analysts have a consensus price target of 316.14 USD. This suggests the asset is currently trading above analyst expectations.

In terms of valuation, the stock trades at a P/E ratio of 85.25. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: ShockWave Medical, Inc. is expected to release its next earnings report on May 6, 2024. The market consensus estimate for Forward EPS is 6.18.

Investor FAQ

Does ShockWave Medical, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is ShockWave Medical, Inc.?

ShockWave Medical, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be May 6, 2024. The company currently has a trailing EPS of 3.84.

Company Profile

Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

Exchange Ticker
NMS (United States) SWAV
FRA (Germany) 36M.F
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion